This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Thanks everyone for joining us. Dave Friedman one of the biotech analyst and in terms of disclosures for myself and Morgan Stanley, you can look on morganstanley.com/researchdisclosures and we’ve team from Alnylam up here; very exciting platform, RNAi company and more. And on the far side here I’ve got Mike Mason, VP of Finance and on the near side, John Maraganore, CEO. And so maybe if you guys want to give a brief sort of statement or overview about the company at all and then we can then just dive right in.
Sure, David thanks and thanks for having us here at the conference. Alnylam is a RNAi therapeutics company that has focused from the beginning on developing small interfering RNA drugs and over the last many years, we really been focused on perfecting the technology so that we can achieve the optimization of these molecules, introducing drug-like properties into these molecules and ultimately delivering these molecules into the right cell types and tissues in the body to be able to harness the indigenous RNAi pathway to create important new medicines.
And I think it's fair to say that over the last two years in particular, the work that we've done on achieving delivery of small interfering RNAs to liver cells and documenting in human trials that we can in fact knock down targeting genes man with very robust pharmacological effects and I think that largely comes out of the work that we’ve done in our transthyretin amyloidosis program, but also the work we've done on our PCSK9 Hypercholesterolemia program.